MSMB在前列腺癌患者血清中的表达及其临床意义

发布时间：2018-05-03 06:23

  本文选题：β-微精浆蛋白 + 前列腺癌　； 参考：《天津医科大学》2014年硕士论文

【摘要】：目的：通过检测前列腺癌(PCa)患者血清MSMB的表达情况,研究其与前列腺癌进展的关系,探讨其在前列腺癌患者中的临床应用价值,为前列腺癌的诊断以及恶性行为评估提供新的标志物,以及理论依据和研究基础。 方法：我们以164人作为研究对象,采用ELISA方法检测97例前列腺癌患者(实验组)和67例良性前列腺增生患者(对照组)的血清MSMB含量,比较两组人群血清MSMB之间的差异,并分析不同临床分期和病理分级(Gleason评分)前列腺癌患者血清MSMB含量之间的差异,以及在不同PSA水平前列腺癌患者血清MSMB含量之间的差异。 结果：ELISA检测发现,前列腺癌患者血清中MSMB的浓度[(6.52±2.99)ng/mL]明显低于良性前列腺增生患者血清中MSMB的浓度[(23.40±15.37)ng/mL](P=0.000)。另外,前列腺癌临床分期≤T2a、=T2B、≥T2c的血清MSMB含量分别为(8.72+1.06)ng/mL、(6.91±1.62)ng/mL、(2.21±1.55)ng/mL(P均0.05)；前列腺癌病理分级Gleason评分≤6、=7、≥8的血清MSMB含量分别为(8.70±1.35)ng/mL、(6.31±0.78)ng/mL、(2.02±1.31)ng/mL(P均0.05),说明不同临床分期和病理分级前列腺癌患者血清MSMB的含量存在明显差异。但前列腺癌PSA10ng/mL(10-20) ng/mL、20ng/mL的血清MSMB含量分别为(6.52±2.86)ng/mL、(7.87±2.26) ng/mL、(5.78±3.23) ng/mL(P=0.052),说明不同PSA水平前列腺癌患者血清MSMB的含量无明显差异。 结论：血清MSMB在前列腺癌的临床诊断方面具有重要的价值,是诊断前列腺癌的一种较理想生物学标记。前列腺癌患者血清MSMB含量明显低于良性前列腺增生患者,且其随前列腺癌临床分期和Gleason评分的增高而降低,可大致判断前列腺癌的浸润度和恶性度,可用于前列腺癌的预后评估。
[Abstract]:Objective: to study the relationship between the expression of serum MSMB and the progression of prostate cancer in patients with prostate cancer (PCA), and to explore its clinical application value in patients with prostate cancer. To provide a new marker for the diagnosis of prostate cancer and the evaluation of malignant behavior, as well as theoretical basis and research basis. Methods: the serum MSMB levels of 97 patients with prostate cancer (experimental group) and 67 patients with benign prostatic hyperplasia (control group) were measured by ELISA method. The difference of serum MSMB between the two groups was compared. The difference of serum MSMB content in prostate cancer patients with different clinical stage and pathological grade (Gleason score) and the difference of serum MSMB content among prostate cancer patients with different PSA level were analyzed. Results the concentration of MSMB in serum of prostate cancer patients [6.52 卤2.99)ng/mL] was significantly lower than that of patients with benign prostatic hyperplasia [23.40 卤15.37)ng/mL]. In addition, The serum MSMB levels of patients with prostate cancer 鈮，

本文编号：1837373